Loading…
Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective
Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The intr...
Saved in:
| Published in: | Future oncology (London, England) England), 2021-12, Vol.17 (35), p.4971-4982 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c343t-f46bc62f2df0d89778bf049a9253ad60330271a2eb0b49b83eb817defd646f5b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c343t-f46bc62f2df0d89778bf049a9253ad60330271a2eb0b49b83eb817defd646f5b3 |
| container_end_page | 4982 |
| container_issue | 35 |
| container_start_page | 4971 |
| container_title | Future oncology (London, England) |
| container_volume | 17 |
| creator | Wilmas, Kelly M Nguyen, Quoc-Bao Patel, Jigar Silapunt, Sirunya Migden, Michael R |
| description | Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist. |
| doi_str_mv | 10.2217/fon-2021-0901 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2579378319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2579378319</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-f46bc62f2df0d89778bf049a9253ad60330271a2eb0b49b83eb817defd646f5b3</originalsourceid><addsrcrecordid>eNp1kDtPwzAURi0EouUxsiKPLAG_GsdsCPGSQCxlthz7ugQ1cWsnSP33OEphY_Jn3XM_6R6ELii5ZozKGx-6ghFGC6IIPUBzKoUoKk7oYc5CqqIslZihk5S-CBGSL8gxmnFRkqoiao7aZQTTt9D1OHhs3LfpLDhsh950EIaE03Yw7RgsrNfYmmibLrTmFhv8Fj7zfIgriDtsOocdxNb0YR1WjcWhs2Pa4Q3EtAHbN99who68WSc437-n6OPxYXn_XLy-P73c370WlgveF16UtS2ZZ84TVykpq9oToYxiC25cSTgnTFLDoCa1UHXFoa6odOBdKUq_qPkpupp6NzFsB0i9bps0HjAdpdlCKi4rTlVGiwm1MaQUwetNbFoTd5oSPRrW2bAeDevRcOYv99VD3YL7o3-VZkBNgB_6IUKyDWSlevrljSYLhH_KfwD_OYy8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579378319</pqid></control><display><type>article</type><title>Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective</title><source>PubMed Central Free</source><creator>Wilmas, Kelly M ; Nguyen, Quoc-Bao ; Patel, Jigar ; Silapunt, Sirunya ; Migden, Michael R</creator><creatorcontrib>Wilmas, Kelly M ; Nguyen, Quoc-Bao ; Patel, Jigar ; Silapunt, Sirunya ; Migden, Michael R</creatorcontrib><description>Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2021-0901</identifier><identifier>PMID: 34608809</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>advanced cutaneous squamous cell carcinoma ; Biomarkers, Tumor ; Carcinoma, Squamous Cell - diagnosis ; Carcinoma, Squamous Cell - etiology ; Carcinoma, Squamous Cell - therapy ; cemiplimab ; Clinical Decision-Making ; Clinical Trials as Topic ; Combined Modality Therapy ; Dermatology - methods ; Dermatology - standards ; Disease Management ; Humans ; immunotherapy ; locally advanced cutaneous squamous cell carcinoma ; Medical Oncology - methods ; Medical Oncology - standards ; metastatic cutaneous squamous cell carcinoma ; Mohs Surgery - adverse effects ; Mohs Surgery - methods ; Mohs Surgery - standards ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; oncholytic immunotherapy ; pembrolizumab ; radiation therapy ; targeted therapy ; Treatment Outcome</subject><ispartof>Future oncology (London, England), 2021-12, Vol.17 (35), p.4971-4982</ispartof><rights>2021 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-f46bc62f2df0d89778bf049a9253ad60330271a2eb0b49b83eb817defd646f5b3</citedby><cites>FETCH-LOGICAL-c343t-f46bc62f2df0d89778bf049a9253ad60330271a2eb0b49b83eb817defd646f5b3</cites><orcidid>0000-0003-4701-9238 ; 0000-0001-6344-319X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34608809$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilmas, Kelly M</creatorcontrib><creatorcontrib>Nguyen, Quoc-Bao</creatorcontrib><creatorcontrib>Patel, Jigar</creatorcontrib><creatorcontrib>Silapunt, Sirunya</creatorcontrib><creatorcontrib>Migden, Michael R</creatorcontrib><title>Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.</description><subject>advanced cutaneous squamous cell carcinoma</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Squamous Cell - diagnosis</subject><subject>Carcinoma, Squamous Cell - etiology</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>cemiplimab</subject><subject>Clinical Decision-Making</subject><subject>Clinical Trials as Topic</subject><subject>Combined Modality Therapy</subject><subject>Dermatology - methods</subject><subject>Dermatology - standards</subject><subject>Disease Management</subject><subject>Humans</subject><subject>immunotherapy</subject><subject>locally advanced cutaneous squamous cell carcinoma</subject><subject>Medical Oncology - methods</subject><subject>Medical Oncology - standards</subject><subject>metastatic cutaneous squamous cell carcinoma</subject><subject>Mohs Surgery - adverse effects</subject><subject>Mohs Surgery - methods</subject><subject>Mohs Surgery - standards</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>oncholytic immunotherapy</subject><subject>pembrolizumab</subject><subject>radiation therapy</subject><subject>targeted therapy</subject><subject>Treatment Outcome</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kDtPwzAURi0EouUxsiKPLAG_GsdsCPGSQCxlthz7ugQ1cWsnSP33OEphY_Jn3XM_6R6ELii5ZozKGx-6ghFGC6IIPUBzKoUoKk7oYc5CqqIslZihk5S-CBGSL8gxmnFRkqoiao7aZQTTt9D1OHhs3LfpLDhsh950EIaE03Yw7RgsrNfYmmibLrTmFhv8Fj7zfIgriDtsOocdxNb0YR1WjcWhs2Pa4Q3EtAHbN99who68WSc437-n6OPxYXn_XLy-P73c370WlgveF16UtS2ZZ84TVykpq9oToYxiC25cSTgnTFLDoCa1UHXFoa6odOBdKUq_qPkpupp6NzFsB0i9bps0HjAdpdlCKi4rTlVGiwm1MaQUwetNbFoTd5oSPRrW2bAeDevRcOYv99VD3YL7o3-VZkBNgB_6IUKyDWSlevrljSYLhH_KfwD_OYy8</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Wilmas, Kelly M</creator><creator>Nguyen, Quoc-Bao</creator><creator>Patel, Jigar</creator><creator>Silapunt, Sirunya</creator><creator>Migden, Michael R</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4701-9238</orcidid><orcidid>https://orcid.org/0000-0001-6344-319X</orcidid></search><sort><creationdate>20211201</creationdate><title>Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective</title><author>Wilmas, Kelly M ; Nguyen, Quoc-Bao ; Patel, Jigar ; Silapunt, Sirunya ; Migden, Michael R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-f46bc62f2df0d89778bf049a9253ad60330271a2eb0b49b83eb817defd646f5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>advanced cutaneous squamous cell carcinoma</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Squamous Cell - diagnosis</topic><topic>Carcinoma, Squamous Cell - etiology</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>cemiplimab</topic><topic>Clinical Decision-Making</topic><topic>Clinical Trials as Topic</topic><topic>Combined Modality Therapy</topic><topic>Dermatology - methods</topic><topic>Dermatology - standards</topic><topic>Disease Management</topic><topic>Humans</topic><topic>immunotherapy</topic><topic>locally advanced cutaneous squamous cell carcinoma</topic><topic>Medical Oncology - methods</topic><topic>Medical Oncology - standards</topic><topic>metastatic cutaneous squamous cell carcinoma</topic><topic>Mohs Surgery - adverse effects</topic><topic>Mohs Surgery - methods</topic><topic>Mohs Surgery - standards</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>oncholytic immunotherapy</topic><topic>pembrolizumab</topic><topic>radiation therapy</topic><topic>targeted therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilmas, Kelly M</creatorcontrib><creatorcontrib>Nguyen, Quoc-Bao</creatorcontrib><creatorcontrib>Patel, Jigar</creatorcontrib><creatorcontrib>Silapunt, Sirunya</creatorcontrib><creatorcontrib>Migden, Michael R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilmas, Kelly M</au><au>Nguyen, Quoc-Bao</au><au>Patel, Jigar</au><au>Silapunt, Sirunya</au><au>Migden, Michael R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>17</volume><issue>35</issue><spage>4971</spage><epage>4982</epage><pages>4971-4982</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>34608809</pmid><doi>10.2217/fon-2021-0901</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-4701-9238</orcidid><orcidid>https://orcid.org/0000-0001-6344-319X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2021-12, Vol.17 (35), p.4971-4982 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2579378319 |
| source | PubMed Central Free |
| subjects | advanced cutaneous squamous cell carcinoma Biomarkers, Tumor Carcinoma, Squamous Cell - diagnosis Carcinoma, Squamous Cell - etiology Carcinoma, Squamous Cell - therapy cemiplimab Clinical Decision-Making Clinical Trials as Topic Combined Modality Therapy Dermatology - methods Dermatology - standards Disease Management Humans immunotherapy locally advanced cutaneous squamous cell carcinoma Medical Oncology - methods Medical Oncology - standards metastatic cutaneous squamous cell carcinoma Mohs Surgery - adverse effects Mohs Surgery - methods Mohs Surgery - standards Molecular Targeted Therapy Neoplasm Metastasis Neoplasm Staging oncholytic immunotherapy pembrolizumab radiation therapy targeted therapy Treatment Outcome |
| title | Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A08%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20advanced%20cutaneous%20squamous%20cell%20carcinoma:%20a%20Mohs%20surgery%20and%20dermatologic%20oncology%20perspective&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Wilmas,%20Kelly%20M&rft.date=2021-12-01&rft.volume=17&rft.issue=35&rft.spage=4971&rft.epage=4982&rft.pages=4971-4982&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2021-0901&rft_dat=%3Cproquest_cross%3E2579378319%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c343t-f46bc62f2df0d89778bf049a9253ad60330271a2eb0b49b83eb817defd646f5b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2579378319&rft_id=info:pmid/34608809&rfr_iscdi=true |